{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:03:52Z","timestamp":1789675432052,"version":"4.0.1"},"reference-count":31,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Pretreatment drug resistance (PDR) poses an increasing threat to the effectiveness of antiretroviral therapy and treatment-as-prevention strategies. Zhejiang Province, an economically developed region in eastern China with high population mobility, experiences complex HIV-1 subtype dynamics and evolving resistance patterns. However, recent population-based evidence integrating HIV genetic subtypes, PDR prevalence, and associated factors remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to characterize HIV-1 subtype distribution, estimate the prevalence of PDR, and identify associated demographic, virological, and prophylaxis-related factors among newly diagnosed individuals in Zhejiang Province from 2022 to 2024.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a cross-sectional study among adults newly diagnosed with HIV-1 in Zhejiang Province between 2022 and 2024. Demographic, epidemiological, laboratory, and exposure prophylaxis information was collected through the provincial HIV surveillance system. Partial Pol gene sequences were amplified and sequenced to determine HIV subtypes and drug resistance mutations. PDR was interpreted using the Stanford University HIV Drug Resistance Database. Logistic regression models were applied to identify factors associated with PDR.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 8798 newly diagnosed individuals, the predominant subtypes were CRF07_BC (n=3913, 44.5%), CRF01_AE (n=2524, 28.7%), and CRF08_BC (n=954, 10.8%), with significant heterogeneity across age groups, sexes, transmission routes, and diagnosis years (\n P<\/jats:italic>\n <.001). Overall PDR prevalence was 5.7% (n=504), with resistance mainly to nonnucleoside reverse-transcriptase inhibitors (n=352, 4.0%). The most frequently detected mutations were K103N, M184V, and M46L. Multivariable analysis showed that higher baseline CD4 cell counts, diagnosis in 2023 and 2024, and infection with the CRF01_AE subtype were independently associated with increased odds of PDR. Pre-exposure prophylaxis was not associated with overall PDR; however, drug-specific analyses demonstrated significant associations between exposure prophylaxis and pretreatment resistance to emtricitabine (\n P<\/jats:italic>\n <.001) and lamivudine (\n P<\/jats:italic>\n <.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n HIV-1 genetic diversity in Zhejiang Province remains complex and dynamic, accompanied by an increasing prevalence of PDR. Although exposure prophylaxis was not linked to overall PDR, its association with emtricitabine-specific resistance highlighted the need for strengthened HIV-1 testing prior to prophylaxis initiation and enhanced resistance surveillance, but they require confirmation in future studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/96139","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:11:21Z","timestamp":1789672281000},"page":"e96139-e96139","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study"],"prefix":"10.2196","volume":"12","author":[{"given":"Wei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1887-9776","authenticated-orcid":false,"given":"Qin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4288-5516","authenticated-orcid":false,"given":"Jiafeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9374-468X","authenticated-orcid":false,"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiezhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-2733","authenticated-orcid":false,"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-992X","authenticated-orcid":false,"given":"Chengliang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3373-3393","authenticated-orcid":false,"given":"Xiaohong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"R1","unstructured":"UNAIDS global AIDS update 2025: AIDS, crisis and the power to transform. UNAIDS; 2025. URL: https:\/\/www.unaids.org\/en\/UNAIDS-global-AIDS-update-2025 [Accessed 02-09-2026]"},{"issue":"10425","key":"R2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0140-6736(23)01381-8","article-title":"HIV epidemiology, prevention, treatment, and implementation strategies for public health","volume":"403","author":"Mody","journal-title":"Lancet"},{"issue":"9","key":"R3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa","volume":"215","author":"Phillips","journal-title":"J Infect Dis"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001-2017)","volume":"18","author":"Zuo","journal-title":"EClinicalMedicine"},{"key":"R5","unstructured":"HIV drug resistance \u2013 brief report 2024. World Health Organization; 2024. URL: https:\/\/www.who.int\/publications\/i\/item\/9789240086319 [Accessed 02-09-2026]"},{"issue":"2","key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad016","article-title":"Disparity of HIV-1 pretreatment drug resistance in men who have sex with men and the heterosexual population in Guangxi, China","volume":"10","author":"Pang","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2595793","article-title":"Deep sequencing reveals underestimated burden of integrase inhibitor resistance mutations in people living with HIV: a global individual patient data meta-analysis","volume":"14","author":"Yuan","journal-title":"Emerg Microbes Infect"},{"key":"R8","unstructured":"National Free Antiretroviral Therapy Manual. National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention; 2023."},{"issue":"11","key":"R9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir","volume":"226","author":"Margot","journal-title":"J Infect Dis"},{"issue":"10","key":"R10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jmv.24223","article-title":"Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou, China","volume":"87","author":"Zhang","journal-title":"J Med Virol"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02193-x","article-title":"HIV-1 drug resistance and genetic transmission network among newly diagnosed people living with HIV\/AIDS in Ningbo, China between 2018 and 2021","volume":"20","author":"Hong","journal-title":"Virol J"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02528-2","article-title":"Transmitted drug resistance and molecular transmission network among treatment-naive HIV-1 patients in Wenzhou, China, 2020-2023","volume":"21","author":"Zhang","journal-title":"Virol J"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02734-6","article-title":"Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023","volume":"22","author":"Li","journal-title":"Virol J"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s15010-024-02389-5","article-title":"Insights into the molecular network characteristics of major HIV-1 subtypes in developed Eastern China: a study based on comprehensive molecular surveillance data","volume":"53","author":"Fan","journal-title":"Infection"},{"issue":"18","key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"Struck","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"R16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1089\/aid.1995.11.1413","article-title":"A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences","volume":"11","author":"Siepel","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29937","article-title":"Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China","volume":"96","author":"Lv","journal-title":"J Med Virol"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.2196\/50894","article-title":"Pretreatment HIV drug resistance and the molecular transmission network among HIV-positive individuals in China in 2022: multicenter observational study","volume":"9","author":"Chen","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"R19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28973","article-title":"Characteristics of genotype, drug resistance, and molecular transmission network among newly diagnosed HIV-1 infections in Shenzhen, China","volume":"95","author":"Li","journal-title":"J Med Virol"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S406255","article-title":"Genetic diversity and characteristics of drug resistance among treatment-naive people living with HIV in Xi\u2019an, China","volume":"17","author":"Xia","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12981-024-00646-z","article-title":"HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016\u20132023)","volume":"21","author":"Gao","journal-title":"AIDS Res Ther"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1017\/S0950268817003016","article-title":"Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing","volume":"146","author":"Song","journal-title":"Epidemiol Infect"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13252","article-title":"Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China","volume":"23 Suppl 1","author":"Gao","journal-title":"HIV Med"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02455-2","article-title":"Molecular transmission network analysis reveals the challenge of HIV-1 in ageing patients in China: elderly people play a crucial role in the transmission of subtypes and high pretreatment drug resistance in developed Eastern China, 2019-2023","volume":"21","author":"Cao","journal-title":"Virol J"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2373105","article-title":"Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021","volume":"15","author":"Zhang","journal-title":"Virulence"},{"issue":"Suppl 1","key":"R26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hiv.13253","article-title":"Pretreatment drug resistance in people living with HIV: a large retrospective cohort study in Chongqing, China","volume":"23 Suppl 1","author":"Liu","journal-title":"HIV Med"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02704-y","article-title":"Divergent transmission dynamics and drug resistance evolution of HIV-1 CRF01_AE and CRF07_BC in Tianjin, China (2013-2022)","volume":"22","author":"Minna","journal-title":"Virol J"},{"issue":"6","key":"R28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug resistance during HIV pre-exposure prophylaxis","volume":"79","author":"Gibas","journal-title":"Drugs"},{"issue":"2","key":"R29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/QAI.0000000000002638","article-title":"Acute HIV at the time of initiation of pre-exposure or post-exposure prophylaxis: impact on drug resistance and clinical outcomes","volume":"87","author":"Johnson","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/S2352-3018(23)00290-4","article-title":"HIV self-testing, PrEP, and drug resistance: some insights","volume":"11","author":"Ochieng","journal-title":"Lancet HIV"},{"issue":"3","key":"R31","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1016\/S2352-3018(23)00268-0","article-title":"Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study","volume":"11","author":"Cox","journal-title":"Lancet HIV"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:11:23Z","timestamp":1789672283000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2026\/1\/e96139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":31,"URL":"https:\/\/doi.org\/10.2196\/96139","relation":{},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"v12i10425e96139"}}